Fate Therapeutics, Inc. (FATE) Stock Price

FATEStock

$2.55+112.17%52W

Market Cap$305.54M

P/E—

PEG Ratio—

Div yield—

Beta2.55

FATE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)66.86%

Price vs S&P 500 (4W)2.12%

VGM Score40.83

Book Value / Share (Quarterly)$1.55

P/TBV (Annual)0.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-58.98%

Cash Flow / Share (Quarterly)$-0.93

Price vs S&P 500 (YTD)137.02%

Net Profit Margin (TTM)-2056.79%

EPS (TTM)$-1.09

10-Day Avg Trading Volume1.68M

EPS Excl Extra (TTM)$-1.09

Revenue Growth (5Y)-26.71%

EPS (Annual)$-1.15

ROI (Annual)-62.60%

Net Profit Margin (5Y Avg)-868.65%

Cash / Share (Quarterly)$1.50

Revenue Growth QoQ (YoY)-20.26%

ROA (Last FY)-42.74%

Revenue Growth TTM (YoY)-52.64%

EBITD / Share (TTM)$-1.06

ROE (5Y Avg)-51.48%

Operating Margin (TTM)-2207.47%

Cash Flow / Share (Annual)$-0.97

P/B Ratio1.63x

P/B Ratio (Quarterly)0.78x

Net Income / Employee (Annual)$-846,700

EV / Revenue (TTM)41.91x

Net Interest Coverage (TTM)-2.83x

ROA (TTM)-39.39%

EPS Incl Extra (Annual)$-1.15

Current Ratio (Annual)5.79x

Quick Ratio (Quarterly)5.72x

3-Month Avg Trading Volume3.43M

52-Week Price Return112.17%

Revenue / Employee (TTM)$39,200

Tangible BV / Share (Quarterly)$4.09

P/S Ratio (Annual)44.20x

Asset Turnover (Annual)0.02x

52-Week High$3.23

Operating Margin (5Y Avg)-954.74%

EPS Excl Extra (Annual)$-1.15

CapEx CAGR (5Y)3.84%

Tangible BV CAGR (5Y)44.36%

26-Week Price Return78.10%

Quick Ratio (Annual)5.69x

13-Week Price Return16.19%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)5.85x

Enterprise Value$264.72M

Revenue / Share Growth (5Y)-31.89%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-16.35%

Revenue / Employee (Annual)$41,300

Pretax Margin (Annual)-2051.08%

Cash / Share (Annual)$1.77

3-Month Return Std Dev99.29%

Net Income / Employee (TTM)$-806,900

ROE (Last FY)-65.79%

Net Interest Coverage (Annual)-2.02x

EPS Basic Excl Extra (Annual)$-1.15

Receivables Turnover (TTM)4.06x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-1.09

Receivables Turnover (Annual)2.58x

ROI (TTM)-56.96%

P/S Ratio (TTM)46.51x

Pretax Margin (5Y Avg)-868.65%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$4.97

Price vs S&P 500 (52W)93.86%

Year-to-Date Return148.98%

5-Day Price Return-4.69%

EPS Normalized (Annual)$-1.15

ROA (5Y Avg)-35.95%

Net Profit Margin (Annual)-2051.08%

Month-to-Date Return-0.41%

Cash Flow / Share (TTM)$-1.58

EBITD / Share (Annual)$-1.13

Operating Margin (Annual)-2222.45%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-50.65%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-1.09

P/TBV (Quarterly)0.58x

P/B Ratio (Annual)0.55x

Pretax Margin (TTM)-2056.79%

Book Value / Share (Annual)$1.80

Price vs S&P 500 (13W)13.40%

Beta2.55x

Revenue / Share (TTM)$0.05

ROE (TTM)-58.89%

52-Week Low$0.93

vGradeD

gGradeF

mGradeB

vgmGradeC

FATE Earnings Surprise History

Q2 25-0.29est. -0.34

Q3 25-0.27est. -0.28

Q4 25-0.27est. -0.27

Q1 26-0.26est. -0.28

Q2 26-0.25est. -0.26

FATE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.89

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
FATEFate Therapeutics, Inc.	D	F	B	$2.55
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company developing cell-based immunotherapies targeting cancer and autoimmune disorders. The platform uses engineered natural killer and T cells derived from clonal master iPSC lines, alongside immunoregulatory candidates designed to prevent serious treatment complications.